Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around
Principal Investigator
by Lyudmilla Bazhenova, MD (ucsd)
Headshot of Lyudmilla Bazhenova
Lyudmilla Bazhenova

Description

Summary

The purpose of the study is to determine whether plinabulin (also known as BPI-2358) has an effect on cancer and body in combination with nivolumab, a standard treatment for metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.

Plinabulin inhibits tumor growth by targeting both new and existing blood vessels going to the tumor as well as killing tumor cells. Plinabulin is an investigational drug, a drug that is not approved for use outside of research studies by regulatory agencies. Up to 38 patients will be enrolled.

Official Title

A Phase I Study of Nivolumab in Combination With Escalating Doses of Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Details

Keywords

Non-small Cell Lung Cancer Metastatic, Metastatic, NSCLC, nivolumab, plinabulin, BPI-2358, opdivo, Non-Small Cell Lung Cancer, cancer, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Nivolumab + Plinabulin

Eligibility

Location

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States

Lead Scientist at University of California Health

  • Lyudmilla Bazhenova, MD (ucsd)
    Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Lyudmila Bazhenova, M.D.
ID
NCT02812667
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 18 people participating
Last Updated